MedTrace Logo

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

NCT05191784 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-06-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

Conditions

Interventions

DRUG

GX-I7

Administered by intramuscular (IM) injection

DRUG

Bevacizumab

Administered by intravenous (IV) injection

Sponsors & Collaborators

  • Genexine, Inc.

    lead INDUSTRY

Principal Investigators

  • Minkyu Heo · Genexine, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-26
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191784 on ClinicalTrials.gov